

# CEPI'S MAJOR PROGRAMMATIC ACHIEVEMENTS

2017 to present

## ENABLING PROJECTS

### Centralised lab network



Established a global network of **17+ laboratories** to support priority pathogen vaccine R&D

### Preclinical models network



Established a global network of **16 facilities**

### Manufacturing network



Established a network of **5 Global South** manufacturing partners

### Epidemiology study



Launched ENABLE, the **largest-ever** Lassa epidemiology study


## CEPI FIRSTS

### Nipah



Advanced the **first ever** Nipah vaccine into **Phase 2** trials

### Rift Valley fever




Advanced RVF vaccine into **Phase 2** trials

### MERS



Advanced the **first ever** MERS vaccine into **Phase 2** trials

### Lassa fever




Advanced the **first ever** Lassa virus vaccine into **Phase 2** trials

### Chikungunya



First **licensed** Chikungunya vaccine


### Innovations



Supported the **first medical product** designed using **AI** to be approved for any indication anywhere in the world.


## CORONAVIRUSES

### COVID-19



Supported **14** COVID-19 vaccine candidates  
**4** granted **EUL**  
**3** approved for domestic use

### BPCV



**World's leading funder** of vaccine R&D, investing in **13** broadly protective coronavirus vaccine candidates

### COVAX launched and co-led by CEPI



Nearly **2 billion** vaccines



shipped to **146 countries**



**2.7 million** deaths averted in lower-income countries

## FILOVIRUSES

### Ebola



Supported generation of data to support expanded access and licensed vaccines

### Marburg

**10 DAYS**

Supported Rwandan led response which deployed vaccine into a clinical trial